For TET1, overexpression has been reported in both MLL-rearranged leukemia and cytogenetically normal AML patients and was found to be correlated with a poor OS in the latter group, thus suggesting a pro-oncogenic role for TET1 in hematological cancers (161, 162). Here, TET1 is linked to acute myeloid leukemia.